An update on pathogenesis of psoriatic arthritis and potential therapeutic targets

References

• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:14–17.
   Web of Science ®Google Scholar
• Chimenti MS, Triggianese P, Nuccetelli M, et al. Auto-reactions, autoimmunity and psoriatic arthritis. Autoimmun Rev. 2015;14:1142–1146.
   PubMed Web of Science ®Google Scholar
• Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973;32:181–201.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Ballanti E, Perricone C, et al. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev. 2013;12:599–606.
   PubMed Web of Science ®Google Scholar
• Pica F, Chimenti MS, Gaziano R, et al. Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases. Clin Exp Immunol. 2016;186:39–45.
   PubMed Web of Science ®Google Scholar
• Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev. 2015;14(4):286–292.
   PubMed Web of Science ®Google Scholar
• Dolcino M, Lunardi C, Ottria A, et al. Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis. PLoS ONE. 2014;16:e115424.
   Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376:957–970.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Triggianese P, Botti E, et al. S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis. J Int Med Res. 2016;44(1 suppl):33–37.
   PubMedGoogle Scholar
• Ballanti E, Perricone C, Greco E, et al. Complement and autoimmunity. Immunol Res. 2013;56:477–491.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Pool B, Smith T, et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther. 2010;12(4):R164.
   PubMed Web of Science ®Google Scholar
• Breban M. Genetics of spondyloarthritis. Best Pract Res Clin Rheumatol. 2006;20(3):593–599.
   PubMed Web of Science ®Google Scholar
• Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Prim. 2016;2:16082.
   PubMed Web of Science ®Google Scholar
• Bowes J, Budu-Aggrey A, Huffmeier U, et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat Commun. 2015;6:6046.
   PubMed Web of Science ®Google Scholar
• Stuart PE, Nair RP, Tsoi LC, et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. 2015;97:816–836.
   PubMed Web of Science ®Google Scholar
• Jadon DR, Sengupta R, Nightingale A, et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis. 2017 Apr;76(4):701–707.
   PubMed Web of Science ®Google Scholar
• Winchester R, Minevich G, Steshenko V, et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum. 2012;64:1134–1144.
   PubMed Web of Science ®Google Scholar
• Haroon M, Winchester R, Giles JT, et al. Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis. Clin Exp Rheumatol. 2017;35:270–276.
   PubMed Web of Science ®Google Scholar
• Cubino N, Montilla C, Usategui-Martín R, et al. Association of IL1Β (−511 A/C) and IL6 (−174 G > C) polymorphisms with higher disease activity and clinical pattern of psoriatic arthritis. Clin Rheumatol. 2016;35(7):1789–1794.
   PubMed Web of Science ®Google Scholar
• Berinstein J, Pollock R, Pellett F, et al. Association of variably expressed KIR3dl1 alleles with psoriatic disease. Clin Rheumatol. 2017;36(10):2261–2266.
   PubMed Web of Science ®Google Scholar
• Eder L, Abji F, Rosen CF, et al. The association of HLA-class I genes and the extent of atherosclerotic plaques in patients with psoriatic disease. J Rheumatol. 2016;43:1844–1851.
   PubMed Web of Science ®Google Scholar
• Jadon D, Tillett W, Wallis D, et al. Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. Rheumatology (Oxford). 2013;52(2):261–266.
   PubMed Web of Science ®Google Scholar
• Bojko A, Ostasz R, Białecka M, et al. IL12B, IL23A, IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment. Hum Immunol. 2018;79:213–217.
   PubMed Web of Science ®Google Scholar
• López de Castro JA. How ERAP1 and ERAP2 shape the peptidomes of disease-associated MHC-I proteins. Front Immunol. 2018;9:2463.
   PubMed Web of Science ®Google Scholar
• Chandran V, Bull SB, Pellett FJ, et al. Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatology (Oxford). 2014;53:233–239.
   PubMed Web of Science ®Google Scholar
• Lambert S, Swindell WR, Tsoi LC, et al. Dual role of Act1 in keratinocyte differentiation and host defense: TRAF3IP2 silencing alters keratinocyte differentiation and inhibits IL-17 responses. J Invest Dermatol. 2017;137(7):1501–1511.
   PubMed Web of Science ®Google Scholar
• Giardina E, Hüffmeier U, Ravindran J, et al. Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus. Arthritis Rheum. 2011;63(12):3801–3806.
   PubMedGoogle Scholar
• Apel M, Uebe S, Bowes J, et al. Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum. 2013;65(5):1224–1231.
   PubMedGoogle Scholar
• Yukinori O, Buhm H, Lam CT, et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet. 2014;95(2):162–172.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Aydin SZ, Gül A, et al. ‘MHC-I-opathy’-unified concept for spondyloarthritis and behçet disease. Nat Rev Rheumatol. 2015;11(12):731–740.
   PubMed Web of Science ®Google Scholar
• Song GG, Kim JH, Lee YH. Associations between the major histocompatibility complex class I chain-related gene A transmembrane (MICA-TM) polymorphism and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis. Rheumatol Int. 2014;34:117–123.
   PubMed Web of Science ®Google Scholar
• Chandran V, Bull SB, Pellett FJ, et al. Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Hum Imm. 2013;74(10):1333–1338.
   PubMed Web of Science ®Google Scholar
• Pollock R, Chandran V, Barrett J, et al. Differential major histocompatibility complex class I chain-related A allele associations with skin and joint manifestations of psoriatic disease. Tissue Antigens. 2011;77:554–561.
   PubMedGoogle Scholar
• Huffmeier U, Mossner R. Complex role of TNF variants in psoriatic arthritis and treatment response to anti-TNF therapy: evidence and concepts. J Investig Dermatol. 2014;134:2483–2485.
   PubMed Web of Science ®Google Scholar
• Karam RA, Zidan HE, Khater MH. Polymorphisms in the TNF- α and IL-10 gene promoters and risk of psoriasis and correlation with disease severity. Cytokine. 2014;66:101–105.
   PubMed Web of Science ®Google Scholar
• Rahman P, Siannis F, Butt C, et al. TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis. 2006;65:919–923.
   PubMed Web of Science ®Google Scholar
• Reich K, Hüffmeier U, König IR, et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum. 2007;56:2056–2064.
   PubMedGoogle Scholar
• Rahman P, Inman RD, Maksymowych WP, et al. Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol. 2009;36(1):137–140.
   PubMed Web of Science ®Google Scholar
• Zhu KJ, Zhu CY, Shi G, et al. Meta-analysis of IL12B polymorphisms (rs3212227, rs6887695) with psoriasis and psoriatic arthritis. Rheumatol Int. 2013;33(7):1785–1790.
   PubMed Web of Science ®Google Scholar
• Pelosi A, Lunardi C, Fiore PF, et al. MicroRNA expression profiling in psoriatic arthritis. Biomed Res Int. 2018;2018:7305380.
   PubMed Web of Science ®Google Scholar
• Chatzikyriakidou A, Voulgari PV, Georgiou I, et al. The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. Scand J Immunol. 2010;71(5):382–385.
   PubMed Web of Science ®Google Scholar
• Hermann H, Runnel T, Aab A, et al. miR-146b probably assists miRNA-146a in the suppression of keratinocyte proliferation and inflammatory responses in psoriasis. J Invest Dermatol. 2017 Sep;137(9):1945–1954.
   PubMed Web of Science ®Google Scholar
• Zhang W, Yi X, Guo S, et al. A single-nucleotide polymorphism of miR-146a and psoriasis: an association and functional study. J Cell Mol Med. 2014 Nov;18(11):2225–2234.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Nikamo P, Lohcharoenkal W, et al. MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis. J Allergy Clin Immunol. 2017;139:550–561.
   PubMed Web of Science ®Google Scholar
• Chen HX, Liu YS, Zhang XJ. Target score used to reveal potential targets of miRNA203 and miRNA-146a in psoriasis by integrating microRNA overexpression and microarray data. Medicine (Baltimore). 2018;97:e12671.
   PubMed Web of Science ®Google Scholar
• Ciancio G, Ferracin M, Saccenti E, et al. Characterisation of peripheral blood mononuclear cell microRNA in early onset psoriatic arthritis. Clin Exp Rheumatol. 2017;35:113–121.
   PubMed Web of Science ®Google Scholar
• Xu WD, Pan HF, Li JH, et al. MicroRNA-21 with therapeutic potential in autoimmune diseases. Expert Opin Ther Targets. 2013;17:659–665.
   PubMed Web of Science ®Google Scholar
• Dolcino M, Pelosi A, Fiore PF, et al. Long non-coding RNAs play a role in the pathogenesis of psoriatic arthritis by regulating microRNAs and genes involved in inflammation and metabolic syndrome. Front Immunol. 2018;9:1533.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Padula A, D’Angelo S, et al. Role of trauma in psoriatic arthritis. J Rheumatol. 2008;35:2085–2087.
   PubMed Web of Science ®Google Scholar
• Taylor-Gjevre RM, Nair B, Gjevre J, et al. Trauma and psoriatic arthritis: is there a relationship? Can Fam Physician. 2012;58(11):e636–40.
   PubMed Web of Science ®Google Scholar
• Hsieh J, Kadavath S, Efthimiou P. Can traumatic injury trigger psoriatic arthritis? A review of the literature. Clin Rheumatol. 2014;33(5):601–608.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Jiang WY, Raychaudhuri SK. Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol. 2008;172:961–7118.
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822(1):21–33.
   PubMed Web of Science ®Google Scholar
• Pearce FL, Thompson HL. Some characteristics of histamine secretion from rat peritoneal mast cells stimulated with nerve growth factor. J Physiol. 1986;372:379–393.
   PubMed Web of Science ®Google Scholar
• Thorpe LW, Werrbach-Perez K, Perez-Polo JR. Effects of nerve growth factor on the expression of IL-2 receptors on cultured human lymphocytes. Ann NY Acad Sci. 1987;496:310–311.
   PubMed Web of Science ®Google Scholar
• Lambiase A, Bracci-Laudiero L, Bonini S, et al. Human CD4+T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors. J Allergy Clin Immunol. 1997;100:408–414.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Raychaudhuri SP, Weltman H, et al. Effect of nerve growth factor on endothelial cell biology: proliferation and adherence molecule expression on human dermal microvascular endothelial cells. Arch Dermatol Res. 2001;293:291–295.
   PubMed Web of Science ®Google Scholar
• Naukkarinen A, Nickoloff BJ, Farber EM. Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J Invest Dermatol. 1989;92:126–129.
   PubMed Web of Science ®Google Scholar
• Al’Abadie MS, Senior HJ, Bleehen SS, et al. Neuropeptides and general neuronal marker in psoriasis: an immunohistochemical study. Clin Exp Dermatol. 1995;20:384–389.
   PubMed Web of Science ®Google Scholar
• Wallengren J, Ekman R, Sunder F. Occurrence and distribution of neuropeptides in human skin. an immune-cytochemical and immuno-histochemical study on normal skin and blister fluid from inflamed skin. Ac-Ta Derm Venereol. 1987;67:185–192.
   PubMed Web of Science ®Google Scholar
• Aloe L. Nerve growth factor and neuroimmune responses: basic and clinical observations. Arch Physiol Biochem. 2001;109:354–356.
   PubMedGoogle Scholar
• Hattori A, Iwasaki S, Murase K, et al. Tumor necrosis factor is markedly synergistic with interleukin1 and interferon gamma in stimulating the production of nerve growth factor in fibroblasts. FEBS Lett. 1994;340:177–180.
   PubMed Web of Science ®Google Scholar
• Moalem G, Gdalyahu A, Shani Y, et al. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Autoimmun. 2000;15(3):331–345.
   PubMed Web of Science ®Google Scholar
• Levine JD, Clark R, Devor M, et al. Intraneuronal substance P con-tributes to the severity of experimental arthritis. Science. 1984;226:547–549.
   PubMed Web of Science ®Google Scholar
• Jacques P, McGonagle D. The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Pract Res Clin Rheumatol. 2014;28(5):703–710.
   PubMed Web of Science ®Google Scholar
• Jacques P, Lambrecht S, Verheugen E, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis. 2014;73:437–445.
   PubMed Web of Science ®Google Scholar
• Sakkas LI, Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev. 2017;16:10–15.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Tan AL, Watad A, et al. Pathophysiology, assessment and treatment of psoriatic dactylitis. Nat Rev Rheumatol. 2019;15:113–122.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Tan AL. The enthesis in psoriatic arthritis. Clin Exp Rheumatol. 2015;33:36–39.
   PubMed Web of Science ®Google Scholar
• Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752–1761.
   PubMed Web of Science ®Google Scholar
• Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells con-tribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15:914–920.
   PubMed Web of Science ®Google Scholar
• Versini M, Jeandel PY, Rosenthal E, et al. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13:981–1000.
   PubMed Web of Science ®Google Scholar
• Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul. 2009;43:157–168.
   PubMedGoogle Scholar
• Ikuni N, Lam QL, Lu L, et al. Leptin and Inflammation. Curr Immunol Rev. 2008;4:70–79.
   PubMedGoogle Scholar
• Krysiak R, Handzlik-Orlik G, Okopien B. The role of adipokines in connective tissue diseases. Eur J Nutr. 2012;51:513–528.
   PubMed Web of Science ®Google Scholar
• Cañete JD, Mease P. The link between obesity and psoriatic arthritis. Ann Rheum Dis. 2012;71(8):1265–1266.
   PubMed Web of Science ®Google Scholar
• Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford). 2013;52(1):62–67.
   PubMed Web of Science ®Google Scholar
• Sun Y, Xun K, Wang C, et al. Adiponectin, an unlocking adipocytokine. Cardiovasc Ther. 2009;27(Spring):59–75.
   PubMedGoogle Scholar
• Chimenti MS, Triggianese P, Conigliaro P, et al. The interplay between inflammation and metabolism in rheumatoid arthritis. Cell Death Dis. 2015;6:e1887.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Ramonda R, et al. Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res. 2015;61(1–2):147–153.
   PubMed Web of Science ®Google Scholar
• Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018;13(5):e0195123.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, et al. Impact of 24 month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014;33(6):833–839.
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken). 2013;65:141–147.
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Peluso R, Iervolino S, et al. CaRRDs study group. weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014;73(6):1157–1162.
   PubMed Web of Science ®Google Scholar
• Eppinga H, Konstantinov SR, Peppelenbosch MP, et al. The microbiome and psoriatic arthritis. Curr Rheumatol Rep. 2014;16:407.
   PubMed Web of Science ®Google Scholar
• Van Praet L, Van Den Bosch F, Mielants H, et al. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep. 2011;13:409–415.
   PubMed Web of Science ®Google Scholar
• Scarpa R, Manguso F, D’Arienzo A, et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000;27:1241–1246.
   PubMed Web of Science ®Google Scholar
• Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55:205–211.
   PubMed Web of Science ®Google Scholar
• Collado MC, Derrien M, Isolauri E, et al. Intestinal integrity and akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol. 2007;73:7767–7770.
   PubMed Web of Science ®Google Scholar
• Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–180.
   PubMed Web of Science ®Google Scholar
• Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015;67:128–139.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Perricone C, Novelli L, et al. Interaction between microbiome and host genetics in psoriatic arthritis. Autoimmun Rev. 2018;17(3):276–283.
   PubMed Web of Science ®Google Scholar
• Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347:911–920.
   PubMed Web of Science ®Google Scholar
• Peluso R, Iervolino S, Vitiello M, et al. Extra-articular manifestations in psoriatic arthritis patients. Clin Rheumatol. 2015;34:745–753.
   PubMed Web of Science ®Google Scholar
• Moen K, Brun JG, Valen M, et al. Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. Clin Exp Rheumatol. 2006;24:656–663.
   PubMed Web of Science ®Google Scholar
• Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2:372–377.
   PubMed Web of Science ®Google Scholar
• Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010;34:J258–65.
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;31:1–8.
   Google Scholar
• Li W, Han J, Qureshi AA. Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012;71:804–808.
   PubMed Web of Science ®Google Scholar
• Zhao S, Jones GT, Macfarlane GJ, et al. Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR biologics register for ankylosing spondylitis (BSRBR-AS). Rheumatology (Oxford). 2019;58:811–819.
   Google Scholar
• Wenink MH, Santegoets KC, Butcher J, et al. Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis. Arthritis Rheum. 2011;63(11):3313–3322.
   PubMedGoogle Scholar
• Lories RJ, de Vlam K. Is psoriatic arthritis a result of abnormalities in acquired or innate immunity? Curr Rheumatol Rep. 2012;14(4):375–382.
   PubMed Web of Science ®Google Scholar
• Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol. 2004;4:211–222.
   PubMed Web of Science ®Google Scholar
• Candia L, Marquez J, Hernandez C, et al. Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients psoriatic arthritis: a pathogenic role for innate immunity? J Rheumatol. 2007;3:374–379.
   Google Scholar
• Akbal A, Oğuz S, Gökmen F, et al. C-reactive protein gene and Toll-like receptor 4 gene polymorphisms can relate to the development of psoriatic arthritis. Clin Rheumatol. 2015;34(2):301–306.
   PubMed Web of Science ®Google Scholar
• Carrasco S, Neves FS, Fonseca MH, et al. Toll-like receptor (TLR) 2 is upregulated on peripheral blood monocytes of patients with psoriatic arthritis: a role for a gram-positive inflammatory trigger?. Clin Exp Rheumatol. 2011;29(6):958–962.
   PubMed Web of Science ®Google Scholar
• Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev. 2015;14(4):286–292.
   PubMed Web of Science ®Google Scholar
• Su F, Xia Y, Huang M, et al. Expression of NLPR3 in psoriasis is associated with enhancement of interleukin-1β and caspase-1. Med Sci Monit. 2018;24:7909–7913.
   PubMed Web of Science ®Google Scholar
• Zotti T, Polvere I, Voccola S, et al. CARD14/CARMA2 signaling and its role in inflammatory skin disorders. Front Immunol. 2018;9:2167.
   PubMed Web of Science ®Google Scholar
• Israel L, Mellett M. Clinical and genetic heterogeneity of CARD14 mutations in psoriatic skin disease. Front Immunol. 2018;9:2239.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55:379–390.
   PubMed Web of Science ®Google Scholar
• Boutet MA, Nerviani A, Gallo Afflitto G, et al. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):530.
   PubMed Web of Science ®Google Scholar
• Suzuki E, Mellins ED, Gershwin ME, et al. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13:496–502.
   PubMed Web of Science ®Google Scholar
• Cai Y, Shen X, Ding C, et al. Pivotal role of dermal IL-17-producingγδT cells in skin inflammation. Immunity. 2011;35:596–610.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Passacantando A, Perricone R, et al. T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen. Clin Exp Rheumatol. 2001;19:317–320.
   PubMed Web of Science ®Google Scholar
• Benham H, Norris P, Goodall J, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther. 2013;15:R136.
   PubMed Web of Science ®Google Scholar
• Leijten EF, van Kempen TS, Boes M, et al. Brief report: enrichment of activated group 3 innate lym-phoid cells in psoriatic arthritis synovial fluid. Arthritis Rheumatol. 2015;67:2673–2678.
   PubMed Web of Science ®Google Scholar
• Res PC, Piskin G, de Boer OJ, et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One. 2010;5:e14108.
   PubMed Web of Science ®Google Scholar
• Triggianese P, Conigliaro P, Chimenti MS, et al. Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis. Clin Exp Rheumatol. 2016;34:1085–1093.
   PubMed Web of Science ®Google Scholar
• Villanova F, Flutter B, Tosi I, et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol. 2014;134:984–991.
   PubMed Web of Science ®Google Scholar
• Ward NL, Umetsu DT. A new player on the psoriasis block: IL-17A-and IL-22-producing innate lymphoid cells. J Invest Dermatol. 2014;134:2305–2307.
   PubMed Web of Science ®Google Scholar
• Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses. Nat Immunol. 2008;9:650–657.
   PubMed Web of Science ®Google Scholar
• Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol. 2008;181:5948–5955.
   PubMed Web of Science ®Google Scholar
• Keijsers RR, Joosten I, van Erp PE, et al. van de kerkhof PC. cellular sources of IL-17 in psoriasis: a paradigm shift? Exp Dermatol. 2014;23(11):799–803.
   PubMed Web of Science ®Google Scholar
• Aochi S, Tsuji K, Sakaguchi M, et al. Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages. J Am Acad Dermatol. 2011;64:879–887.
   PubMed Web of Science ®Google Scholar
• Inciarte-Mundo J, Ramirez J, Hernández MV, et al. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1 year prospective cohort study. Arthritis Res Ther. 2018;20:275.
   PubMed Web of Science ®Google Scholar
• Berntzen HB, Munthe E, Fagerhol MK. A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol. 1989;16:1416–1420.
   PubMed Web of Science ®Google Scholar
• Hansson C, Eriksson C, Alenius G-M. S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res. 2014;2014:696415.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Ødegård S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007;66:1093–1097.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Ødegård S, Syversen SW, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:150–154.
   PubMed Web of Science ®Google Scholar
• Carubbi F, Chimenti MS, Blasetti G, et al. Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated dermatology/rheumatology outpatient clinics. J Eur Acad Dermatol Venereol. 2015;29:2160–2168.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Spinelli FR, Giunta A, et al. Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review. Drug Dev Res. 2014;75(Suppl 1):S61–3.
   PubMedGoogle Scholar
• Saraceno R, Chimenti MS, Chimenti S. The significance of the development of antinuclear antibodies during infliximab treatment. J Am Acad Dermatol. 2013;69(2):314.
   PubMed Web of Science ®Google Scholar
• Conigliaro P, Chimenti M, Triggianese P, et al. Autoantibodies in inflammatory arthritis. Autoimmun Rev. 2016;15(7):673–683.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Qiu J, Lin ZT, et al. Identification of novel autoantibodies associated with psoriatic arthritis. Arthritis Rheumatol. 2019;71:941–951.
   PubMed Web of Science ®Google Scholar
• Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621.
   PubMed Web of Science ®Google Scholar
• Frasca L, Palazzo R, Chimenti MS, et al. Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: new biomarkers in PsA. Front Immunol. 2018;9:193.
   PubMed Web of Science ®Google Scholar
• Rosenberg EW, Noah PW, Wyatt RJ, et al. Complement activation in psoriasis. Clin Exp Dermatol. 1990;15:16–20.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Perricone C, Graceffa D, et al. Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment. Clin Exp Rheumatol. 2012;30:23–30.
   PubMed Web of Science ®Google Scholar
• Ballanti E, Perricone C, Di Muzio G, et al. Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev. 2011;10:617–623.
   PubMed Web of Science ®Google Scholar
• Partsch G, Bauer K, Bröll H, et al. Complement C3 cleavage product in synovial fluids detected by immunofixation. Z Rheumatol. 1991;50:82–85.
   PubMed Web of Science ®Google Scholar
• Schett G, Lories RJ, D’Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13(12):731–741.
   PubMed Web of Science ®Google Scholar
• Siannis F, Farewell VT, Cook RJ, et al. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis. 2006;65:478–481.
   PubMedGoogle Scholar
• Simon D, Faustini F, Kleyer A, et al. Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Ann Rheum Dis. 2016;75:660–666.
   PubMed Web of Science ®Google Scholar
• Paine A, Ritchlin C. Bone remodelling in psoriasis and psoriatic arthritis: an update. Curr Opin Rheumatol. 2016;28:66–75.
   PubMed Web of Science ®Google Scholar
• Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modelling and remodelling. Arch Biochem Biophys. 2008;473:139–146.
   PubMed Web of Science ®Google Scholar
• Danks L, Komatsu N, Guerrini MM, et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann Rheum Dis. 2016;75:1187–1195.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Investig. 2003;111:821–831.
   PubMed Web of Science ®Google Scholar
• Partsch G, Wagner E, Leeb BF, et al. Upregulation of cytokine receptors sTNF-R55, sTNF- R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol. 1998;25:105–110.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni CE, Gladman D, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65(8):1038–1043.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264–2272.
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007;57:269–275.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Teoli M, Saraceno R, et al. Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics. Dermatology. 2013;227(4):305–310.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24 week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73:233–237.
   PubMed Web of Science ®Google Scholar
• Anandarajah AP, Schwarz EM, Totterman S, et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis. 2008;67:296–301.
   PubMed Web of Science ®Google Scholar
• Benham H, Norris P, Goodall J, et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther. 2013;15:R136.
   PubMed Web of Science ®Google Scholar
• Hüffmeier U, Lascorz J, Böhm B, et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol. 2009;129:355–358.
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One. 2011;6:e17160.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18:1069–1076.
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Investig. 1999;103:1345–1352.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewe RB, Mease PJ, et al. Brief report: secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol. 2016;68:1914–1921.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Harter L, Shin D, et al. The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. Ann Rheum Dis. 2017;76:882–885.
   PubMedGoogle Scholar
• Chandran S, Aldei A, Johnson SR, et al. Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review. Semin Arthritis Rheum. 2016;46:174–182.
   PubMed Web of Science ®Google Scholar
• McGonagle D. Imaging the joint and enthesis: insights into pathogenesis of psoriatic arthritis. Ann Rheum Dis. 2005;64(Suppl 2):ii58–i60.
   PubMedGoogle Scholar
• Paine A, Ritchlin C. Altered bone remodeling in psoriatic disease: new insights and future directions. Calcif Tissue Int. 2018;102:559–574.
   PubMed Web of Science ®Google Scholar
• Lu Z, Wang G, Dunstan CR, et al. Short-term exposure to tumor necrosis factor-alpha enables human osteoblasts to direct adipose tissue-derived mesenchymal stem cells into osteogenic differentiation. Stem Cells Dev. 2012;21:2420–2429.
   PubMed Web of Science ®Google Scholar
• Cho HH, Shin KK, Kim YJ, et al. NF-kappaB activation stimulates osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue by increasing TAZ expression. J Cell Physiol. 2010;223:168–177.
   PubMed Web of Science ®Google Scholar
• Wang Z, Jia Y, Du F, et al. IL-17A inhibits osteogenic differentiation of bone mesenchymal stem cells via WNT signalling pathway. Med Sci Monit. 2017;23:4095–4101.
   PubMed Web of Science ®Google Scholar
• Croes M, Oner FC, van Neerven D, et al. Proinflammatory T cells and IL-17 stimulate osteoblast differentiation. Bone. 2016;84:262–270.
   PubMed Web of Science ®Google Scholar
• Ono T, Okamoto K, Nakashima T, et al. IL-17-producing gammadelta T cells enhance bone regeneration. Nat Commun. 2016;7:10928.
   PubMed Web of Science ®Google Scholar
• Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Investig. 2005;115:1571–1579.
   PubMed Web of Science ®Google Scholar
• Abd-Elsalam N, Kamel N, Zamzam M, et al. The relation between serum bone morphogenetic protein-7 and severity of enthesitis in psoriatic arthritis. Egypt Rheumatol Rehabil. 2013;40:129–133.
   Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 american college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019;71:2–29.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM. The role of IL-17 in the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2017;13:815–821.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017;56:1993–2003.
   PubMed Web of Science ®Google Scholar
• Mease PJ, van der Heijde D, Ritchlin CT, et al. SPIRIT-P1 study group. ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24 week randomised,double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79–87.
   PubMed Web of Science ®Google Scholar
• Giunta A, Ventura A, Chimenti MS, et al. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy. Drug Des Devel Ther. 2017;11:1643–1651.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52 week results from a phase iii study (SPIRIT-P1). J Rheumatol. 2018;45:367–377.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Combe B, Kremer JM, et al. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology (Oxford). 2018;57:2001–2011.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370:2295–2306.
   PubMed Web of Science ®Google Scholar
• Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13:722–728.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Ortolan A, Lorenzin M, et al. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24 month prospective multicentric study. Clin Rheumatol. 2018;37:397–405.
   PubMed Web of Science ®Google Scholar
• Křížová L, Kuchař M, Petroková H, et al. p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells. Autoimmunity. 2017;50:102–113.
   PubMed Web of Science ®Google Scholar
• Wechter T, Cline A, Feldman SR. Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. Ther Clin Risk Manage. 2018;14:1489–1497.
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276–288.
   PubMed Web of Science ®Google Scholar
• Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376:1551–1560.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Gottlieb AB, Boehncke WH, et al. CNTO1959PSA2001 study group. efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391:2213–2224.
   PubMed Web of Science ®Google Scholar
• Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1311–1316.
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537–1550.
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525–1536.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1843–1847.
   PubMed Web of Science ®Google Scholar
• Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Faleri S, Saraceno R, et al. Tofacitinib for the treatment of moderate-to-severe psoriasis. Expert Rev Clin Immunol. 2015;11:443–455.
   PubMed Web of Science ®Google Scholar
• Wang CJ, Heuts F, Ovcinnikovs V, et al. CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement. Proc Natl Acad Sci U S A. 2015;112:524–529.
   PubMed Web of Science ®Google Scholar
• Esensten JH, Helou YA, Chopra G, et al. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44:973–988.
   PubMed Web of Science ®Google Scholar
• Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63(4):939–948.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gottlieb AB, van der Heijde D, et al. Ef cacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo- controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76(9):1550–1558.
   PubMed Web of Science ®Google Scholar
• Noisette A, Hochberg MC. Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives. Psoriasis (Auckl). 2018;8:31–39.
   PubMed Web of Science ®Google Scholar
• Khatri A, Othman AA. Population pharmacokinetics of the TNF-α and IL-17A dual-variable domain antibody ABT-122 in healthy volunteers and subjects with psoriatic or rheumatoid arthritis: analysis of phase 1 and 2 clinical trials. J Clin Pharmacol. 2018;58:803–813.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Wagner F, Kivitz AJ, et al. Safety, tolerability, and pharmacodynamics of ABT-122, a tumor necrosis factor and interleukin-17-targeted dual variable domain immunoglobulin, in patients with rheumatoid arthritis. Arthritis Rheumatol. 2017;69:2283–2291.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Weinblatt ME, et al. Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate. Arthritis Rheumatol. 2018;70:1778–1789.
   PubMed Web of Science ®Google Scholar
• Jacobson KA, Merighi S, Varani K, et al. A(3) adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy. Med Res Rev. 2018;38:1031–1072.
   PubMed Web of Science ®Google Scholar
• Ravani A, Vincenzi F, Bortoluzzi A, et al. Role and function of A(2A) and A₃ adenosine receptors in patients with ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis. Int J Mol Sci. 2017;18.
   PubMed Web of Science ®Google Scholar
• David M, Gospodinov DK, Gheorghe N, et al. Treatment of plaque-type psoriasis with oral CF101: data from a phase ii/iii multicenter,randomized, controlled trial. J Drugs Dermatol. 2016;15:931–938.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Ferrante A, et al. Interleukin-9 overex- pression and Th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis. Arthritis Rheumatol. 2016;68:1922–1931.
   PubMed Web of Science ®Google Scholar
• Novelli L, Chimenti MS, Chiricozzi A, et al. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmun Rev. 2014;13:64–69.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76:418–431.
   PubMed Web of Science ®Google Scholar
• Zweegers J, Groenewoud JMM, van Den Reek JMPA, et al. Comparison of the 1- and 5 year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry. Br J Dermatol. 2017 Apr;176(4):1001–1009.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Becciolini A, Caporali R, et al. GISEA study group. the profiling of axial spondyloarthritis patient candidate to a biologic therapy: consensus from a delphi-panel of Italian experts. Autoimmun Rev. 2018;17(12):1251–1258.
   PubMed Web of Science ®Google Scholar
• Noureldin B, Barkham N. The current standard of care and the unmet needs for axial spondyloarthritis. Rheumatology (Oxford). 2018;57(suppl 6):vi10–vi17.
   PubMedGoogle Scholar
• Perricone C, de Carolis C, Perricone R. Pregnancy and autoimmunity: a common problem. Best Pract Res Clin Rheumatol. 2012;26:47–60.
   PubMed Web of Science ®Google Scholar
• Fassio A, Gatti D, Rossini M, et al. Secukinumab produces a quick increase in WNT signaling antagonists in patients with psoriatic arthritis. Clin Exp Rheumatol. 2019;37(1):133–136.
   Google Scholar
• Costa L, Del Puente A, Peluso R, et al. Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother. 2017;18:1557–1567.
   PubMed Web of Science ®Google Scholar
• Jimenez-Boj E, Stamm TA, Sadlonova M, et al. Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis. 2012;71(11):1868–1871.
   PubMed Web of Science ®Google Scholar
• Goll GL, Haavardsholm EA, Kvien TK. The confidence of rheumatologists about switching to biosimilars for their patients. Joint Bone Spine. 2018;85:507–509.
   PubMed Web of Science ®Google Scholar